Mukai M, Den N, Yamazaki Y, Namiki S, Oda S, Nagao K
Gan To Kagaku Ryoho. 1982 Jan;9(1):96-102.
We have developed OMF treatment which is consisting of endoscopical injection of OK-432 into the perilesional area of cancer, intraarterial or intravenous injection of mitomycin C by one shot and oral administration of 5-FU, and applied it to the patients with preoperative gastric cancer to whom remarkable macroscopic effects were obtained. We determined its efficacy by establishing a response criteria. Although there were no excellent results, the clinical results were rated as good in 5 lesions (50%) and as fair in 5 lesions (50%) out of 10 lesions in 9 cases. In none of the cases, the treatment was ineffective.
我们研发了OMF治疗方法,包括在内镜下将OK-432注射到癌灶周围区域,一次性动脉内或静脉内注射丝裂霉素C,以及口服5-氟尿嘧啶,并将其应用于术前胃癌患者,取得了显著的宏观效果。我们通过建立反应标准来确定其疗效。虽然没有优异的结果,但在9例患者的10个病灶中,5个病灶(50%)的临床结果评为良好,5个病灶(50%)评为中等。所有病例中治疗均未无效。